🇺🇸 FDA
Patent

US 12420113

Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy

granted A61KA61K31/4725A61P

Quick answer

US patent 12420113 (Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy) held by The Board of Regents of the University of Texas System expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4725, A61P, A61P35/00